NCT04315558View on ClinicalTrials.gov

Revefenacin in Acute Respiratory Insufficiency in COPD

PHASE2CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

November 1, 2020

Primary Completion Date

January 1, 2025

Study Completion Date

January 1, 2025

Conditions
COPDAcute Respiratory Failure
Interventions
DRUG

Revefenacin Inhalation Solution [Yupelri]

nebulized drug comparison

DRUG

Ipratropium Bromide

nebulized drug comparison

Trial Locations (2)

90095

Ronald Reagan Medical Center at UCLA, Los Angeles

90404

Santa Monica UCLA, Santa Monica

Sponsors
All Listed Sponsors
collaborator

Theravance Biopharma

INDUSTRY

collaborator

Mylan Pharmaceuticals Inc

INDUSTRY

lead

University of California, Los Angeles

OTHER

NCT04315558 - Revefenacin in Acute Respiratory Insufficiency in COPD | Biotech Hunter | Biotech Hunter